Artizan Biosciences Announces Corporate Progress and Financing

NEW HAVEN, Conn., June 10, 2019 (GLOBE NEWSWIRE) — Artizan Biosciences, Inc., a biotechnology company focused on addressing inflammatory diseases involving the human intestinal microbiota, today announced corporate and financial updates. The company is leveraging its proprietary IgA-SEQ™ technology platform to identify the putative disease-driving bacteria in Inflammatory Bowel Disease (IBD) from the intestinal microbiota in humans with the goal of developing new and potentially curative treatments.